脑部放疗，上午比下午敏感许多！% b/ c: c, e" l0 H% o
: z3 V! }9 a1 O8 z
! e9 V+ e- c0 g2 x, }Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.
* R5 E* I; J* M* `( e( n. XGamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?
- q" @. F9 E" |5 v6 tRahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
l% B+ Y" {. l$ P( p' ?SourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.
: ]/ g5 F# X$ q9 ~) b( r- B ?- |; ~7 _" S9 _/ M- U; X
Abstract# f+ D8 u9 {9 b6 M$ O2 @
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.: i) S! w1 q8 |! n+ V2 }) p8 k K2 d# Z
' {" a. \& |3 O& o, Q- A! Z0 s
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.
, W4 v5 v+ A ]7 p; H$ E a7 Q
. x) U- k! i3 K sRESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).0 L* c l- o: \( \
7 o6 \( J% E# Q, F7 D: D. }0 s1 Z* Z* ZCONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.
; ~' @3 v1 ^2 I/ ^6 d0 ~- p( K7 i7 j* b" G0 b9 n0 _
|
徐一鹏教授直播开讲！尿路上皮癌复发
作者：雨过天晴在泌尿系统恶性肿瘤中，尿路上皮癌以其“高发病率、高复发率”的特点，
肺癌用药6个月肿瘤消失，我们的治疗
讲述者：步履皆朝阳整理者：pear
总以为肺癌遥不可及，直到它毫无征兆地闯入我们的生
患者参与临床试验，真的完全“风险自
文 | 韩晓晨. 与癌共舞论坛版主、总法律顾问，北京市时代九和律师事务所律师
在与癌
邻居大爷69岁TP53突变，15个月的治疗
大家好：
病人是我家的邻居大爷，今年69周岁；TP53图片；从确诊到目前已经约15个月
这种可能影响药效增加副作用的“禁忌
作者：闵
靶向药是非小细胞肺癌治疗的重要手段之一，造福了不计其数的病友。很多服用
% H& B' h5 x E' M: ~
显身卡
